89bio reports positive data from Phase 1 clinical trial of BIO89-100
Category: #health  By Mateen Dalal  Date: 2019-05-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

89bio reports positive data from Phase 1 clinical trial of BIO89-100

A clinical-stage biopharmaceutical company, 89bio LTD that focusses on NASH (nonalcoholic steatohepatitis), liver and other metabolic disorders, recently announced positive results from Phase 1 SAD (single ascending dose) study on healthy volunteers of its investigational medicine, BIO89-100. The investigational medicine (BIO89-100) is a long acting glycopegylated FGF21 (fibroblast growth factor 21) analogue for treatment of patients with nonalcoholic steatohepatitis, reports source.

Hank Mansbach, Managing Director & Chief Medical Officer, 89bio said that there were consistent results from preclinical studies of BIO89-100 in its first in-human trial. In the study, the investigational medicine confirmed a favorable safety and a biomarker profile with an enduring response with a single dose. It has been expected that these findings will support weekly and 2-week subcutaneous dosing.

The medicine had robust pharmacodynamic effects across multiple lipid parameters, provided the subjects were healthy volunteers with lipid parameters in the normal range, Mansbach added.

Reportedly, BIO89-100 was mostly safe and well tolerated according to its Phase 1 study. The commonly observed adverse events were headache and injection-site reactions, which were mild. The PK (pharmacokinetic) profile of the medicine was generally a dose proportional with a half-life ranging from 53-100 hours, approximately. At single doses of 9.1 mg or higher, the medicine shows significant improvements as compared to baseline in key lipid parameters, measured at 8 & 15 days. The mean changes in comparison to baseline include decline in triglycerides up to 51% and LDL-C up to 37% along with increase in HDL-C up to 36%.

Rohan Palekar, Chief Executive Officer, 89bio, was reportedly quoted saying that the data from the experiment support the advancement of BIO89-100 in study of patients with liver disease, to assess its potential to address the complex nature of nonalcoholic steatohepatitis.

As per sources close to the matter, the first in-human trial of Bio89-100 was double-blind, single ascending dose study designed, randomized & placebo-controlled to evaluate safety, PK profile, tolerability & immunogenicity. It was tested on 58 healthy adult volunteers.

Source credits: https://www.prnewswire.com/news-releases/89bio-reports-positive-top-line-data-from-phase-1-single-ascending-dose-clinical-trial-of-bio89-100-an-investigational-medicine-for-nash-300854790.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...